Fennec Pharmaceuticals Inc. (FENC) stock
FENCNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/3083% above fair value
$13.09−0.36 (-2.68%)
Close on Nov 20, 2026Market cap $459.03MP/E –Yield –
Fennec Pharmaceuticals gross profit
Gross profit is revenue minus the direct cost of the goods and services sold.
Fennec Pharmaceuticals's gross profit for the twelve months ending Dec 31, 2023 was $19.99M. For fiscal 2023 it was $19.99M, up 1279.8% from the year before.
Annual gross profit
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $19.99M | +1279.8% |
| FY2022 | Dec 31, 2022 | $1.45M | – |
Quarterly gross profit
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2023 | Dec 31, 2023 | $9.05M | – |
| Q3 FY2023 | Sep 30, 2023 | $6.18M | – |
| Q2 FY2023 | Jun 30, 2023 | $3.18M | – |
| Q1 FY2023 | Mar 31, 2023 | $1.58M | – |
See a number that looks wrong?